Log In
Print this Print this

VAL 101, VAL101

  Manage Alerts
Collapse Summary General Information
Company ValiRx plc
DescriptionOligonucleotide-protein fusion molecule against Bcl-2
Molecular Target B cell lymphoma 2 (BCL-2) (BCL2)
Mechanism of ActionBcl-2 inhibitor
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationProstate cancer
Indication DetailsTreat androgen independent prostate cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today